DocGo Inc. 8-K

What Happened
DocGo Inc. (DCGO) announced on April 17, 2026 that director Stephen K. Klasko, MD notified the company he will step down from the Board and his committee roles because he accepted a new healthcare leadership position. The departure will be effective at the conclusion of DocGo’s 2026 Annual Meeting of Stockholders, expected June 16, 2026. The company said the decision was not due to any disagreement with DocGo. In response, the Board appointed long-serving independent director Michael Burdiek as independent Chair of the Board effective at the same time.

Key Details

• Dr. Klasko joined the Board in October 2024 and gave notice on April 17, 2026; departure effective at the conclusion of the annual meeting expected June 16, 2026.
• Michael Burdiek will serve as independent Chair of the Board starting at the Effective Time and will hold the role until a successor is elected or earlier vacancy.
• Jim Travers was added to the Board’s Audit and Compliance Committee and the Nominating and Corporate Governance Committee to replace Dr. Klasko, effective immediately prior to the Effective Time.
• On April 21, 2026 the Board formed a special committee (Vina Leite, Ira Smedra, Michael Burdiek) to help identify corporate efficiencies and cost-reduction opportunities aimed at accelerating profitability; Mr. Burdiek will chair that committee.

Why It Matters
Leadership and committee changes affect board oversight and governance. Appointing an independent Chair and adding an independent member to the audit committee aligns with Nasdaq independence expectations and may strengthen financial and compliance oversight. The new special committee’s explicit focus on efficiencies and cost reductions signals management and the Board are prioritizing a faster path to profitability — a material strategic emphasis for investors to watch. The filing notes the departure is amicable and not due to operational disagreements.